Case reports in ophthalmological medicine · 2026
Central Serous Chorioretinopathy Deteriorated With Everolimus Administration in Advanced Renal Cell Carcinoma: A Case Report.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nemati Mahdi, Niyousha Mohammadreza, Kharazi Banafshe, Hassanpoor Narges
Аннотация
BACKGROUND: Everolimus, an antineoplastic drug, is associated with various systemic adverse effects. This case report is aimed at presenting a novel ophthalmological complication, drug-associated central serous chorioretinopathy (CSCR), following everolimus administration.
METHODS: A 54-year-old male with metastatic renal cell carcinoma presented with blurred vision and metamorphopsia. Comprehensive ophthalmologic examination, including multimodal imaging with optical coherence tomography (OCT), fluorescein angiography (FA), and fundus autofluorescence (FAF), was performed. A thorough review of his medical history and recent medication changes was conducted to identify potential associating factors.
RESULTS: Multimodal imaging confirmed bilateral CSCR with subretinal fluid and pachychoroid features. The only recent change in his medication regimen was the initiation of everolimus (10 mg daily) 1 month prior to symptom onset. All other known risk factors for CSCR, such as corticosteroid use, were absent. Upon discontinuation of everolimus, the patient's symptoms and visual acuity improved. Follow-up OCT imaging demonstrated complete resolution of the subretinal fluid.
CONCLUSION: Everolimus can potentially be a risk factor for subclinical CSCR deterioration in prone population. Ophthalmologists and oncologists should be aware of this rare but significant adverse effect.
METHODS: A 54-year-old male with metastatic renal cell carcinoma presented with blurred vision and metamorphopsia. Comprehensive ophthalmologic examination, including multimodal imaging with optical coherence tomography (OCT), fluorescein angiography (FA), and fundus autofluorescence (FAF), was performed. A thorough review of his medical history and recent medication changes was conducted to identify potential associating factors.
RESULTS: Multimodal imaging confirmed bilateral CSCR with subretinal fluid and pachychoroid features. The only recent change in his medication regimen was the initiation of everolimus (10 mg daily) 1 month prior to symptom onset. All other known risk factors for CSCR, such as corticosteroid use, were absent. Upon discontinuation of everolimus, the patient's symptoms and visual acuity improved. Follow-up OCT imaging demonstrated complete resolution of the subretinal fluid.
CONCLUSION: Everolimus can potentially be a risk factor for subclinical CSCR deterioration in prone population. Ophthalmologists and oncologists should be aware of this rare but significant adverse effect.